CureDuchenne is the nation’s leading nonprofit organization dedicated to funding a cure for Duchenne, the most common and lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys living today. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy.
With a mission to cure Duchenne muscular dystrophy, CureDuchenne breaks the traditional charitable mold and balances passion with business acumen. Our innovative venture philanthropy model funds groundbreaking research, early diagnosis and treatment access. With pioneering education and support programs, our organization drives real change for those with Duchenne muscular dystrophy and their loved ones.
Join us at a free Workshop or Session near you!
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Connect With CureDuchenne
Patient Worthy Posts on Duchenne Muscular Dystrophy
For 21-year-old Tanner Pyeatt, the future is uncertain. Diagnosed with Duchenne muscular dystrophy at the age of four, he gradually lost the use of his legs
During the virtual XVIII International Conference on Duchenne and Becker Muscular Dystrophy, specialty pharmaceutical company Italfarmaco Group (“Italfarmaco”) shared updates regarding various Givinostat clinical development
Anyone with rare and neurological disease can relate: there aren’t a ton of treatment options and there are almost never any cures for our conditions. We often
According to a story from statnews.com, the drug developer Sarepta has recently announced the its clinical trial testing an experimental gene therapy has resumed after
Passsage Bio Passage Bio has just announced that they’ve received 115.5 million dollars to help advance their development of gene therapies. They will begin by
According to a story from BioSpace, the US Food and Drug Administration (FDA) has recently approved the drug golodirsen (marketed as Vyondys 53) as a